Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.770
-0.330-3.63%
Volume:150.35M
Turnover:1.32B
Market Cap:101.05B
PE:22.10
High:9.090
Open:8.900
Low:8.705
Close:9.100
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.39
T/O Rate:1.30%
Dividend:0.34
Dividend Rate:3.84%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.30
PE(LYR):22.10
PS:2.76

Loading ...

Cspc Pharmaceutical Says Phase III Trial of Ha1406 Meets Primary Endpoint

Reuters
·
Jul 27

CSPC PHARMA's Injectable Sirolimus (Albumin-Bound) New Drug Application Accepted by China's NMPA

Stock News
·
Jul 27

CSPC Pharma: Ammoxetine (HA1406) Clears Phase III with Statistically Significant Efficacy in Depression

Bulletin Express
·
Jul 27

CSPC Says China NMPA Accepts Sirolimus Albumin-bound Injection Filing, Grants Priority Review

Reuters
·
Jul 27

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Sirolimus for Injection (Albumin-Bound)

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical - Phase Iii Trial of Ha1406 for Depression Meets Primary Endpoint with Statistical Significance

THOMSON REUTERS
·
Jul 27

CSPC PHARMA (01093) Issues Positive Profit Alert, Expects Significant Interim Net Profit Growth to Around RMB 5.9-6.2 Billion

Stock News
·
Jul 27

CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan

Reuters
·
Jul 27

CSPC Pharmaceutical - Expects H1 2026 Profit Attributable to Owners of Rmb5.9 Bln–RMB6.2 Bln

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical - Expected Result Due to Significant Increase in Licence Fee Income, Others in Hy

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical Group Stock Falls 2.9% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jul 27

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.31 From HK$12.04, Keeps at Buy

MT Newswires Live
·
Jul 27

Movement Alert|CSPC PHARMA Declines 3.16% in Regular Trading, Trading at HK$8.3

Market Focus
·
Jul 27

CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval

Simply Wall St.
·
Jul 27

Hong Kong Stock Market Analysis: ChangXin IPO Pressure Weighs, Agricultural Inflation Risks Boost Related Stocks

Stock News
·
Jul 24

CSPC Pharma Gains NMPA Approval for Once-Monthly Paliperidone Palmitate Injection to Treat Schizophrenia

Bulletin Express
·
Jul 24

CSPC Pharma's Paliperidone Palmitate Injection Receives Market Approval

Stock News
·
Jul 24

CSPC Pharma Wins China Approval for Paliperidone Palmitate Schizophrenia Injection

Reuters
·
Jul 24

CSPC Pharmaceutical - Paliperidone Palmitate Injection Receives Marketing Approval

THOMSON REUTERS
·
Jul 24

CSPC Pharmaceutical Group Stock Rises 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 24